Knowing when to leap: Transitioning between exploitative and explorative R&D

A common perspective is that consistent R&D investment facilitates innovation, while volatile spending implies myopic decision making. However, the benefits to exploiting extant competencies eventually erode, so firms must disrupt their R&D function and explore for new competitive advantage. We suggest that high-performing firms recognize when extant competencies decline and increase exploratory R&D to develop new competencies at the appropriate time. We find that changes in R&D expenditure away from the firm's historic trend, in either direction, are indicative of transitions between exploitative and exploratory R&D and are associated with increased firm performance. Increases in R&D expenditure above the trend are associated with an increased likelihood of highly cited patents, suggesting that firms are making the leap between R&D-based exploitation and exploration. Copyright © 2013 John Wiley & Sons, Ltd.

[1]  I. Cockburn,et al.  Measuring competence?: exploring firm effects in pharmaceutical research , 1994 .

[2]  R. Mudambi,et al.  Professional Guilds, Tension and Knowledge Management , 2009 .

[3]  Richard R. Nelson.  The Rate and Direction of Inventive Activity: Economic and Social Factors , 2015 .

[4]  Andrew Chesher,et al.  Testing the Law of Proportionate Effect , 1979 .

[5]  Denise R. Dunlap,et al.  A Story of Breakthrough vs. Incremental Innovation: Corporate Entrepreneurship in the Global Pharmaceutical Industry , 2010 .

[6]  I. Cockburn,et al.  Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery , 2003 .

[7]  Joel A. C. Baum,et al.  Making the Next Move: How Experiential and Vicarious Learning Shape the Locations of Chains' Acquisitions , 2000 .

[8]  Henry G. Grabowski,et al.  The Determinants of Industrial Research and Development: A Study of the Chemical, Drug, and Petroleum Industries , 1968, Journal of Political Economy.

[9]  B. Kogut,et al.  INTERFIRM COOPERATION AND STARTUP INNOVATION IN THE BIOTECHNOLOGY INDUSTRY. , 1993 .

[10]  S. Klepper.  Entry, Exit, Growth, and Innovation over the Product Life Cycle , 1996 .

[11]  J. DiMasi,et al.  Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.

[12]  B. Kogut,et al.  Localization of Knowledge and the Mobility of Engineers in Regional Networks , 1999 .

[13]  Stephen W. Pruitt,et al.  A Simple Approximation of Tobin's Q , 1994 .

[14]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[15]  C. Hill,et al.  Are institutional investors myopic? A time‐series study of four technology‐driven industries , 1991 .

[16]  Richard Blundell,et al.  Individual effects and dynamics in count data models , 2002 .

[17]  Willow A. Sheremata.  Competing Through Innovation in Network Markets: Strategies for Challengers , 2004 .

[18]  Timothy B. Folta,et al.  Entry in the Presence of Dueling Options , 2004 .

[19]  N. Rosenberg.  Why do firms do basic research (with their own money) , 1990 .

[20]  R. J. House,et al.  Organizations: A Quantum View , 1984 .

[21]  Joel Lexchin,et al.  The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States , 2008, PLoS medicine.

[22]  Z. Griliches,et al.  Patents and R and D: Is There a Lag? , 1986 .

[23]  M. Porter,et al.  HOW MUCH DOES INDUSTRY MATTER , REALLY ? , 1997 .

[24]  Zvi Griliches,et al.  Patents and R&D: is There a Lag? , 1984 .

[25]  Bernadette A. Minton,et al.  The Impact of Cash Flow Volatility on Discretionary Investment and the Costs of Debt and Equity Financing , 1999 .

[26]  Karel Cool,et al.  Asset stock accumulation and sustainability of competitive advantage , 1989 .

[27]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[28]  A. Meredith,et al.  UNITED STATES DEPARTMENT OF COMMERCE , 1999 .

[29]  W. E. Silver,et al.  Economics and Information Theory , 1967 .

[30]  David Robertson,et al.  Product development performance: Strategy, organization, and management in the world auto industry , 1992 .

[31]  F. Scherer,et al.  The link between gross profitability and pharmaceutical R&D spending. , 2001, Health affairs.

[32]  G. Lilien,et al.  The timing of competitive market entry: an exploratory study of new industrial products , 1990 .

[33]  A. Jaffe.  Technological Opportunity and Spillovers of R&D: Evidence from Firms&Apos; Patents, Profits and Market Value , 1986 .

[34]  J. Heckman.  Sample selection bias as a specification error , 1979 .

[35]  J. March.  Exploration and exploitation in organizational learning , 1991, STUDI ORGANIZZATIVI.

[36]  Ram Mudambia,et al.  Proactive R&D management and firm growth: A punctuated equilibrium model , 2015 .

[37]  K. Arrow.  Economic Welfare and the Allocation of Resources for Invention , 1962 .

[38]  Daniel A. Levinthal,et al.  ABSORPTIVE CAPACITY: A NEW PERSPECTIVE ON LEARNING AND INNOVATION , 1990 .

[39]  Bronwyn H Hall,et al.  Market value and patent citations , 2005 .

[40]  Raphael Amit,et al.  The Dynamics of Innovative Activity and Competitive Advantage: The Case of Australian Retail Banking, 1981 to 1995 , 2003, Organ. Sci..

[41]  W. P. Barnett,et al.  Too Much of a Good Thing? Product Proliferation and Organizational Failure , 2001 .

[42]  M. Porter.  Competitive Advantage: Creating and Sustaining Superior Performance , 1985 .

[43]  Robert M Califf,et al.  Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. , 2012, JAMA.

[44]  J. March.  Continuity and Change in Theories of Organizational Action , 1996 .

[45]  Kent D. Miller,et al.  Corporate Risk-Return Relations: Returns Variability Versus Downside Risk , 1996 .

[46]  R. Mudambi.  Location, Control and Innovation in Knowledge-Intensive Industries , 2008 .

[47]  J. March.  Rationality, foolishness, and adaptive intelligence , 2006 .

[48]  John Cantwell,et al.  MNE competence‐creating subsidiary mandates , 2005 .

[49]  S. Finkelstein,et al.  Top Management Team Size, CEO Dominance, and firm Performance: The Moderating Roles of Environmental Turbulence and Discretion , 1993 .

[50]  Curba Morris Lampert,et al.  Entrepreneurship in the large corporation: a longitudinal study of how established firms create breakthrough inventions , 2001 .

[51]  Brian J. Bushee.  The Influence of Institutional Investors on Myopic R&D Investment Behavior , 1999 .

[52]  M. Shubik,et al.  A Behavioral Theory of the Firm. , 1964 .

[53]  Timothy Erickson,et al.  Measurement Error and the Relationship between Investment and q , 2000, Journal of Political Economy.

[54]  E. Ofek,et al.  Diversification's effect on firm value , 1995 .

[55]  R. Katila,et al.  Where do resources come from? The role of idiosyncratic situations , 2004 .

[56]  R. Rumelt.  Strategy, structure, and economic performance , 1974 .

[57]  Jeffrey H. Dyer.  Specialized supplier networks as a source of competitive advantage : Evidence from the auto industry , 1996 .

[58]  Mary J. Benner,et al.  Exploitation, Exploration, and Process Management: The Productivity Dilemma Revisited , 2003 .

[59]  J. March,et al.  Managerial perspectives on risk and risk taking , 1987 .

[60]  Ian D. Turner.  Rationality, Foolishness and Adaptive Intelligence , 2006 .

[61]  Raffaele Oriani,et al.  Uncertainty and the Market Valuation of R&D within a Real Options Logic , 2008 .

[62]  Daniel A. Levinthal,et al.  The myopia of learning , 1993 .

[63]  Charlotte R. Ren,et al.  Niche width revisited: organizational scope, behavior and performance , 2006 .

[64]  John D. Tressler,et al.  Increasing Downside Risk , 1980 .

[65]  Rod Coombs,et al.  A literature-based innovation output indicator , 1996 .

[66]  Patricia M. Dechow,et al.  Executive incentives and the horizon problem: An empirical investigation , 1991 .

[67]  R. Solow.  TECHNICAL CHANGE AND THE AGGREGATE PRODUCTION FUNCTION , 1957 .

[68]  H. P. Sims,et al.  Top Management Team Demography and Process: The Role of Social Integration and Communication , 1994 .

[69]  Sheng Huang.  Executive Compensation and Horizon Incentives: an Empirical Investigation , 2012 .

[70]  M. Lessnoff.  Capitalism, Socialism and Democracy , 1979 .

[71]  Moses Abramovitz,et al.  Resources and Output Trends in the United States since 1870. , 1957 .

[72]  Joseph T. Mahoney,et al.  Strategic Management Journal Research Notes and Commentaries How Dynamics, Management, and Governance of Resource Deployments Influence Firm-level Performance , 2022 .

[73]  Andrew A. Signore,et al.  Pharmaceutical Industry Profile , 2005 .

[74]  G. Dosi.  Technological Paradigms and Technological Trajectories: A Suggested Interpretation of the Determinants and Directions of Technical Change , 1982 .

[75]  Simi Kedia,et al.  Explaining the Diversification Discount , 1999 .

[76]  R. Katila,et al.  Technological acquisitions and the innovation performance of acquiring firms: a longitudinal study , 2001 .

[77]  Constance E. Helfat,et al.  Firm-Specificity in Corporate Applied R&D , 1994 .

[78]  D. Leonard-Barton.  CORE CAPABILITIES AND CORE RIGIDITIES: A PARADOX IN MANAGING NEW PRODUCT DEVELOPMENT , 1992 .

[79]  Daniel A. Levinthal,et al.  Exploration and Exploitation in Organizational Learning , 2007 .

[80]  Joseph T. Mahoney,et al.  Firm‐specific knowledge resources and competitive advantage: the roles of economic‐ and relationship‐based employee governance mechanisms , 2009 .

[81]  David B. Audretsch,et al.  Innovation in Large and Small Firms: An Empirical Analysis , 1988 .

[82]  M. Tushman,et al.  Organizational Transformation as Punctuated Equilibrium: An Empirical Test , 1994 .

[83]  Cynthia A. Montgomery,et al.  Diversification, Ricardian rents, and Tobin's q , 1988 .

[84]  René M. Stulz,et al.  Leverage, Investment, and Firm Growth , 1994 .

[85]  C. Gibson,et al.  THE ANTECEDENTS , CONSEQUENCES , AND MEDIATING ROLE OF ORGANIZATIONAL AMBIDEXTERITY , 2004 .

[86]  I. Cockburn,et al.  Untangling the origins of competitive advantage , 2011 .

[87]  A. Nerkar,et al.  Beyond local search: boundary‐spanning, exploration, and impact in the optical disk industry , 2001 .

[88]  胡盛昌,et al.  《The influence of institutional investors on myopic R＆D investment behavior》述评 , 2012 .

[89]  Jeffrey J. Reuer,et al.  MEASURING ORGANIZATIONAL DOWNSIDE RISK , 1996 .

[90]  Ian C. MacMillan,et al.  Business Unit Strategy and Changes in the Product R&D Budget , 1983 .

[91]  Robert E. Hoskisson,et al.  International Diversification: Effects on Innovation and Firm Performance in Product-Diversified Firms , 1997 .

[92]  Waverly W. Ding,et al.  The Impact of Academic Patenting on the Rate, Quality and Direction of (Public) Research Output , 2009 .

[93]  E. Johnsen.  Richard M. Cyert & James G. March, A Behavioral Theory of The Firm, Prentice-Hall, Inc., Englewood Cliffs, New Jersey, 1963, 332 s. , 1964 .

[94]  James C. T. Mao,et al.  SURVEY OF CAPITAL BUDGETING: THEORY AND PRACTICE , 1970 .

[95]  A simple representation of the Bera–Jarque–Lee test for probit models☆ , 2008 .

[96]  Kim B. Clark,et al.  Product Development in the World Auto Industry , 1987 .

[97]  M. Tushman,et al.  Organizational Environments and Industry Exit: the Effects of Uncertainty, Munificence and Complexity , 2001 .

[98]  Pierre Azoulay,et al.  Superstar Extinction , 2008 .

[99]  Henry G. Grabowski,et al.  A New Look at the Returns and Risks to Pharmaceutical R&D , 1990 .

[100]  Nicholas Argyres.  CAPABILITIES, TECHNOLOGICAL DIVERSIFICATION AND DIVISIONALIZATION , 1996 .

[101]  Sigvald Harryson,et al.  Transformation Networks in Innovation Alliances the Development of Volvo C70 , 2008 .

[102]  Bart Nooteboom,et al.  Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology , 2006 .